heart disease

Healthcare Stocks

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology

Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug…

Ryan Allway
February 20, 2025

These Healthcare Stocks Significantly Outperformed the Industry in 2024

While the stock market broadly experienced significant gains in 2024, a few…

Robin Lefferts
January 27, 2025

Positive Phase 2 Results Signal Promising Future For Cardiol Therapeutics

The future of smaller drug development companies frequently hinges on the results…

Robin Lefferts
June 20, 2024

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx™ led to a marked reduction in the primary efficacy…

Ryan Allway
June 13, 2024

Near-Term Catalysts on the Horizon for Cardiol Therapeutics

Investing in smaller drug development companies requires patience. The journey from discovery…

Robin Lefferts
May 28, 2024

Analyst and Research Coverage Bullish on Cardiol Therapeutics

Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) has in some ways burst…

Robin Lefferts
May 1, 2024

The Impact of Positive Phase 2 Trial Results on a Smaller Company

A few weeks back, we covered the effect an Orphan Drug Designation…

Robin Lefferts
March 12, 2024

The Impact of Orphan Drug Development on a Smaller Company

Orphan drugs treat conditions with less than 200,000 patients annually in the…

Robin Lefferts
February 6, 2024

Distinguished Health Centers and Experts Lead Recurrent Pericarditis, Acute Myocarditis Clinical Trials

Any clinical trial program relies heavily on its administrators, advisors, and designers.…

Robin Lefferts
January 16, 2024

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated…

Ryan Allway
December 5, 2023

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology

These Healthcare Stocks Significantly Outperformed the Industry in 2024

Positive Phase 2 Results Signal Promising Future For Cardiol Therapeutics

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Near-Term Catalysts on the Horizon for Cardiol Therapeutics

Analyst and Research Coverage Bullish on Cardiol Therapeutics

The Impact of Positive Phase 2 Trial Results on a Smaller Company

The Impact of Orphan Drug Development on a Smaller Company

Distinguished Health Centers and Experts Lead Recurrent Pericarditis, Acute Myocarditis Clinical Trials

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Don Kreski

Robin Lefferts

Ryan Allway

Analyzing the Significance of LEEF Brands’ Move into the New York Market

Aduro Clean Technologies: Independent Investor Panel Discussion

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology

LEEF Brands Signs Binding Letter of Intent to Acquire a Tier 1 Processing License in New York, Paving the Way to Enter the $1.5B Cannabis Market in 2025

Sign Up for Our Newsletter